ASH 2023 | The clearance of driver mutations following alloSCT impacts myelofibrosis disease outcomes
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses how the mutation clearance of myeloproliferative neoplasm (MPN)-associated driver mutations after allogeneic stem cell transplantation (SCT) affects subsequent disease outcomes in patients with myelofibrosis. The CALR and MPL driver mutations were cleared faster than JAK2 in the year following SCT, with degree of clearance at 30 and 100 days being a strong predictor of outcomes, including relapse and disease-free survival. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
